Want to see SE:ALZCUR full AI Analyst Report?
AlzeCure Pharma AB (ALZCUR) Stock Statistics & Valuation Metrics
Total Valuation
AlzeCure Pharma AB has a market cap or net worth of SEK 882.54M. The enterprise value is SEK 522.18M.
- Market Cap
- SEK 882.54M
- Enterprise Value
- SEK 522.18M
Share Statistics
AlzeCure Pharma AB has 137,897,340 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 137,897,340
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
AlzeCure Pharma AB’s return on equity (ROE) is -1.45 and return on invested capital (ROIC) is -139.15%.
- Return on Equity (ROE)
- -1.45
- Return on Assets (ROA)
- -0.81
- Return on Invested Capital (ROIC)
- -139.15%
- Return on Capital Employed (ROCE)
- -1.39
- Revenue Per Employee
- 0
- Profits Per Employee
- -4.77M
- Employee Count
- 10
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of AlzeCure Pharma AB is 42.87. AlzeCure Pharma AB’s PEG ratio is 0.66.
- PE Ratio
- 42.87
- PS Ratio
- 9.07
- PB Ratio
- 9.66
- Price to FCF
- -21.52
- Price to Operating Cash Flow
- -21.52
- PEG Ratio
- 0.66
Income Statement
In the last 12 months, AlzeCure Pharma AB had revenue of 0 and earned -47.65M in profits. Earnings per share was -0.47.
- Revenue
- 0
- Gross Profit
- -1.27M
- Operating Income
- -49.37M
- Pretax Income
- -47.67M
- Net Income
- -47.65M
- EBITDA
- -48.10M
- Earnings Per Share (EPS)
- -0.47
Cash Flow
In the last 12 months, operating cash flow was -41.00M and capital expenditures 0, giving a free cash flow of -41.00M billion.
- Operating Cash Flow
- -41.00M
- Free Cash Flow
- -41.00M
- Free Cash Flow per Share
- -0.30
Dividends & Yields
AlzeCure Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.65%
- Earnings Yield
- 3.48%
Stock Price Statistics
- Beta
- 0.35
- 52-Week Price Change
- 232.29%
- 50-Day Moving Average
- 7.29
- 200-Day Moving Average
- 4.05
- Relative Strength Index (RSI)
- 36.14
- Average Volume (3m)
- 321.70K
Important Dates
AlzeCure Pharma AB upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 26, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
AlzeCure Pharma AB as a current ratio of 2.33, with Debt / Equity ratio of 15.55%
- Current Ratio
- 2.33
- Quick Ratio
- 2.33
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.94
- Interest Coverage Ratio
- -180.85
Taxes
In the past 12 months, AlzeCure Pharma AB has paid 18.00K in taxes.
- Income Tax
- 18.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
AlzeCure Pharma AB EV to EBITDA ratio is 34.63, with an EV/FCF ratio of -21.24.
- EV to Sales
- 8.95
- EV to EBITDA
- 34.63
- EV to Free Cash Flow
- -21.24
- EV to Operating Cash Flow
- -21.24
Balance Sheet
AlzeCure Pharma AB has SEK 32.97M in cash and marketable securities with SEK 2.29M in debt, giving a net cash position of SEK 30.68M billion.
- Cash & Marketable Securities
- SEK 32.97M
- Total Debt
- SEK 2.29M
- Net Cash
- SEK 30.68M
- Net Cash Per Share
- SEK 0.22
- Tangible Book Value Per Share
- SEK 0.10
Margins
Gross margin is 99.06%, with operating margin of 24.49%, and net profit margin of 31.56%.
- Gross Margin
- 99.06%
- Operating Margin
- 24.49%
- Pretax Margin
- 31.55%
- Net Profit Margin
- 31.56%
- EBITDA Margin
- 25.85%
- EBIT Margin
- 24.60%
Scores
- Smart Score
- ―
- AI Score
- 50